Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients
Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients
复制标题
散发性甲状腺髓样癌患者的预后标志物和凡德他尼治疗的反应
DOI：
10.1055/s-0035-1547649
复制
发表时间：
2015
影响因子：
1.8
通讯作者：
D. Führer
中科院分区：
文献类型：
--
作者：
V. Tiedje;S. Ting;T. Herold;R. Walter;F. Mairinger;K. Worm;D. Zwanziger;K. Schmid;D. Führer
甲状腺髓样癌（MTC）在75%的病例中零星发生。局部疾病患者预后良好。在转移性疾病中，10年生存率显著降低。对于进行性转移性MTC患者的治疗，目前可获得两种酪氨酸激酶抑制剂，凡德他尼和卡博替尼。
Medullary thyroid cancer (MTC) occurs sporadically in 75% of all cases. In patients with local disease prognosis is excellent. In metastatic disease 10-year survival is significantly decreased. For the therapy of progressive metastatic MTC patients two tyrosine kinase inhibitors, vandetanib and cabozantinib, are currently available.